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Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative condition in which motor neurons are selectively targeted. Although the
underlying cause remains unclear, evidence suggests a role for innate immunity in disease pathogenesis. Neuroinflammation in areas of motor
neuron loss is evident in presymptomatic mouse models of ALS and in human patients. Efforts aimed at attenuating the inflammatory response in
ALS animal models have delayed symptom onset and extended survival. Seemingly conversely, attempts to sensitize cells of the innate immune
system and modulate their phenotype have also shown efficacy. Effectors of innate immunity in the CNS appear to have ambivalent potential to
promote either repair or injury. Because ALS is a syndromic disease in which glutamate excitotoxicity, altered cytoskeletal protein metabolism,
oxidative injury, mitochondrial dysfunction and neuroinflammation all contribute to motor neuron degeneration, targeting inflammation via
modulation of microglial function therefore holds significant potential as one aspect of therapeutic intervention and could provide insight into the
exclusive vulnerability of motor neurons.
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Amyotrophic lateral sclerosis (ALS) is a fatal neurodegen-
erative disease characterized by the selective loss of motor
neurons. It is perhaps the most devastating neurodegenerative
condition because of its insidious onset, rapid progression, and
inevitable endpoint. It is also the most frequently diagnosed
adult-onset motor neuron disease [1] with a world-wide
prevalence of approximately 8 per 100,000. Patients present
with symptoms of both upper and lower motor neuron
degeneration which leads to failure of respiratory muscles and
death on average within 3–5 years [2]. While between 5 and 8%
of ALS cases are familial (fALS), of which 20% harbour
missense mutations in the copper–zinc superoxide dismutase
(SOD1) gene [3], the majority of ALS cases are sporadic
(sALS). Although the etiology of ALS remains to be defined,
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components of the pathological process of ALS include
glutamate excitotoxicity, disturbances in cytoskeletal protein
metabolism (e.g., neurofilament, peripherin), oxidative injury,
altered mitochondrial function and neuroinflammation [5,6].
Although these processes seem disparate, there is increasingly
an understanding that these processes are tightly integrated.
This review will focus on the potential role of neuroinflamma-
tion, mediated predominantly through microglial cells, as a key
determinant of the disease process.
2. Inflammation in the CNS
Inflammation is one aspect of the innate immune response.
Innate immunity is naturally present and is not stimulated by
antigens or mediated by antibodies. It is therefore generally
non-specific and is executed by a variety of phagocytic cells
including circulating neutrophils and monocytes and macro-
phages residing in tissues. The resident macrophage of the CNS
is the microglial cell. Throughout development microglia are
immunologically active and capable of responding to events
associated with CNS organization and formation of the
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exist in a resting state providing surveillance and acting as the
first line of immunological defense. They are highly mobile and
responsive to cues from surrounding cells [7]. In response to a
variety of insults, microglia transform into active, phagocytic
cells that release several products governing the inflammatory
response. This transformation is seen as a morphological
transition from a resting, ramified state to an active amoeboid
state through an intermediate, early activated or “primed” [8]
state. Microglia become primed in response to primary stimuli
from neurons or astrocytes including interferon γ (IFNγ), tu-
mour necrosis factor α (TNFα), macrophage colony stimulating
factor (M-CSF), and granulocyte macrophage colony stimulat-
ing factor (GM-CSF). This involves a thickening of the cell
body and proximal processes, and a resulting intensification of
local surveillance. In this state, they express major histocom-
patibility (MHC) class II molecules and present antigens. In
response to secondary stimuli such as interleukin-1 (IL-1), IL-6,
and TNF-α, microglia exert maximal activity through secretion
of inflammatory mediators (Fig. 1).
It is critical to note that the net effect of microglial activation
can be either to induce repair and regeneration, or to further
neuronal injury. Through the release of anti-inflammatory cyto-Fig. 1. Neuroinflammatory interaction of microglia, neurons, and astrocytes. In the h
surveillance in the neuronal milieu. In response to primary stimuli from neurons and
producing pro-inflammatory cytokines and downregulating expression of growth fact
cells with full phagocytic potential. These cells produce increased quantities of
oxygenating intermediates (ROI), and glutamate. Astrocytes decrease their growth f
residing in the inflammatory microenvironment degenerate via apoptotic mechanismkines, neurotrophins and growth factors, and via controlled
phagocytosis with the removal of presynaptic axon terminals
from damaged neurons (synaptic stripping), microglia can
enhance neuronal repair. Conversely, through the release of pro-
inflammatory cytokines, lysosomal proteases, neurotoxic reac-
tive oxygen radicals and nitrating species, and through astro-
cytic activation and chronic phagocytosis, microglia can
enhance neuronal injury [9,10]. Understanding the mechanisms
by which this delicate balance between neuronal repair and
neuronal injury is modulated is of critical importance to under-
standing the role of the innate immune response in ALS. This
key point is illustrated by the observation that the extent of
neuronal injury in a chimeric model of motor neuron degene-
ration, in which the fALS associated G93A SOD1 mutation is
expressed, is dependant on the extent of non-neuronal cell
pathology [11].
Although microglia are the resident macrophage of the CNS,
CNS macrophages can also originate from recently blood-
derived precursors or from resident perivascular macrophages
and related cells [12]. Evidence from peripheral nerve injury
models suggests that microglia are the principal executors of the
inflammatory response although hematogenous macrophages
[13] and lymphocytes [14] are also recruited to the injury site.ealthy CNS (left) microglia reside in a ramified morphology providing immune
astrocytes (initiating mechanism unknown in ALS), microglia become primed
ors. In response to secondary stimuli microglia become fully activated amoeboid
pro-inflammatory cytokines, reactive nitrating intermediates (RNI), reactive
actor contribution and release glutamate and inflammatory mediators. Neurons
s.
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ficant microglial activation and hematogenous macrophage
entry unless the injury itself involves a breakdown in the blood–
brain barrier [13]. In the context of neurodegeneration, recent
work suggests the robust inflammatory response observed in
symptomatic SOD1G93A transgenic mice is mostly attributable
to proliferation of resident microglia with only a small contri-
bution from infiltrating bone marrow-derived microglia [15].
3. Microglia in ALS
There is considerable morphological and neurochemical
evidence for the proliferation and activation of microglia in
ALS [15,15–25]. These findings are observed in areas of
significant motor neuron loss, including the motor cortex, motor
nuclei of the brainstem, the corticospinal tract and the ventral
horn of the spinal cord [19,26]. Relevant to observations de-
rived from animal models (discussed below), microglial activa-
tion is found even in areas of only mild degeneration [26].
While constitutively expressed in the human brain, macro-
phage-colony stimulating factor (M-CSF) receptor expression is
upregulated in ALS precentral gyrus. Both TNF-α and the
soluble extracellular domains of its receptors TNFRI and
TNFRII are increased in ALS serum [27,28]. An increased
expression of pro-inflammatory cytokines, COX-2 [29–31] and
of microglia-mediated protein oxidative pathology [32] is also
observed in ALS.
The important issue as to when in the course of degeneration
in ALS that microglial activation becomes prominent is being
addressed through neuroimaging studies. Using positron
emission tomography (PET) imaging with in vivo radio-labeled
ligand ([(11)C](R)-PK11195 ) binding to the peripheral benzo-
diazepine binding site (as a marker of microglia), microglial
activation can be observed in patients with ALS [33]. In a
variety of models of motor neuron degeneration, microglial
priming occurs either prior to or concomitantly with the onset of
clinical disease. In these in vivo models, microglial activation
and proliferation increases throughout the disease course [34],
raising the possibility that microglial activation occurs early in
the pathogenesis of ALS (Fig. 2).
In vitro experiments have shown that products released by
activated microglia can lead to motor neuron death via TNF-Fig. 2. Microglial morphology: (A) resting/ramified (arrow head), primed/ramified
immunolabeled using Iba-1 antibody (Wako). Magnification 400× prior to reproducα-mediated apoptotic mechanisms [35] and by Fas ligand or
NO-induced apoptotic pathways [36]. It has also been
demonstrated that microglia derived from mutant SOD1
transgenic mice have increased cytotoxic potential in culture
[37]. Using a chimeric mutant SOD1 model in which only a
proportion of cells express the mutant transgene, it has been
observed that the extent of motor neuron injury varies in
severity proportionate to the extent of non-neuronal cells
expressing the mutant transgene [11]. In this latter model, non-
transgenic motor neurons surrounded by glia expressing the
mutant SOD1 transgene degenerated while transgenic motor
neurons surrounded by non-transgenic glia remained healthy.
This study suggests that SOD1 mutations, once thought to
selectively confer motor neuron susceptibility, can result in
glial-mediated neurotoxicity. A recent review cited work from
Don Cleveland's group suggesting that genetic knock-down of
mutant SOD1 in cells of the macrophage lineage can
significantly slow the progression of ALS [38]. Note,
however, that other non-neuronal cells interacting with
motor neurons, such as the skeletal muscle will also express
mutant SOD1 and could contribute to the health of motor
neurons. These experiments have been interpreted to support
the concept that non-neuronal cells, and in this case microglia
specifically, are key determinants of both the timing of
induction and the rate of propagation of motor neuron
degeneration in ALS. In contrast to these studies, transgenic
mice in which SOD1G37R expression is driven by the mouse
prion promoter, resulting in levels of mutant SOD1 expression
highest in neurons and astrocytes in the CNS and in muscle,
develop motor neuron disease despite a lack of expression of
the mutant protein in cells of the macrophage lineage
including microglia [39].
4. The role of the inflammatory response in experimental
motor neuron degeneration
To date, the most direct evidence of a temporal association
between inflammation and the progression of motor neuron
disease in ALS arises from the study of murine models of motor
neuron degeneration, including the wobbler mouse (wr/wr)
[40], the mnd mouse [41,42], and the low-molecular weight
neurofilament knockout mouse (NFL−/−) [43]. In both the(arrow); (B) a cluster of highly activated/amoeboid microglia. Macrophages
tion.
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expression and up-regulation of pro-inflammatory factors in the
presymptomatic phase with a prominent and sustained micro-
glial response is observed throughout the active phase of the
disease progression [44–50]. Specifically, both TGF-β1 and M-
CSF expression are upregulated in presymptomatic mice, with
TNF-α expression being increased well in advance of the
appearance of motor deficits. A significant increase in microglia
numbers is observed in early symptomatic mice [45]. This
process is associated with an increased level of COX-2 mRNA
and protein, and an increase in PGE2 content limited to the
regions associated with motor neuron pathology, further
confirming a role for microglial activation [31,51]. The latter
observation is consistent with in vitro observations that the
motor neuron death induced by chronic glutamate excitotoxicity
in organotypic spinal cord cultures can be suppressed by COX-2
inhibition [52]. Motor neuron disease is accelerated by chronic
stimulation of inflammation using LPS in the SOD1G37R mouse
model of ALS, with increasing levels of pro-inflammatory
cytokines and increased expression of toll-like receptor 2
(TLR-2) [53].
We have also observed an association between microglial
activation and neuronal viability in a model of chronic motor
neuron degeneration induced by monthly intracisternal inocu-
lums of aluminum chloride. In this, the presence of a microglial
proliferative response was a critical determinant of the extent of
recovery upon cessation of aluminum exposure [54–56]. In
vitro, both organic and inorganic aluminum compounds were
found to inhibit microglial activation in the absence of micro-
glial death and to inhibit microglial-mediated motor neuron
death [57]. This suggested that the inhibition of microglial
activation by aluminum chloride in vivo allowed for a neuronal
milieu permissive to motor neuron recovery. We confirmed this
using an immortalized murine motor neuron hybridoma (NSC-
34) [58] to demonstrate that activated microglia can kill motor
neurons by a mechanism that is dependant on the microglial
release of factor(s) that act synergistically with TNF-α. This
process can be fully inhibited by inhibiting microglial activa-
tion. Floden and colleagues reported that conditioned media
obtained from β-amyloid-stimulated primary mouse microglia
induces neurotoxicity in primary cortical neurons via coincident
stimulation of TNF-α and NMDA receptors. Stimulation of
either TNF-α or NMDA receptors alone does not initiate cell
death. Memantine and 2-amino-5-phosphopetanoic acid,
NMDA receptor antagonists, and soluble TNF-α receptor pro-
tect neurons from microglial-conditioned media-dependent
death which is thought to result from oxidative damage
resulting from inducible nitric oxide synthase (iNOS) activity
[59]. NSC-34 cell death can be triggered by oxidative injury
mediated through hydroxynonenal (HNE) formation and the
triggering of apoptosis [60], suggesting that another potential
pathway of microglial-mediated motor neuron injury could be
through the release of reactive oxygen species.
While these studies speak to the toxicity of microglia to
cultured neurons, including primary motor and cortical neurons
and a motor neuron cell line, an important consideration in the
context of ALS is the selective vulnerability of motor neurons invivo. Motor neurons derived from mutant SOD1 transgenic
mice exhibit an increased susceptibility to activation of a Fas-
triggered cell death pathway that is unique to motor neurons and
which is dependent on transcriptional upregulation of neuronal
NOS [36]. This work may offer an explanation for the sensi-
tivity of motor neurons in particular to Fas ligand and NO-
triggered cell death mediated at least in part by neighbouring
microglia, as trophic deprivation and excitotoxic stimulation did
not have similar effects.
While these in vitro and in vivo data suggest that inflam-
matory products released by microglia can act to mediate motor
neuron injury, the mechanism of induction of the microglial
response is unknown. In models of direct axonal injury, such as
a proximal axotomy, a prominent proliferation and migration of
microglia to the perineuronal region occurs within 24 h of the
lesion—implying that the injured neuron possesses the inherent
capacity to induce a microglial response following injury
[61,62]. This suggests a capacity for the motor neuron itself to
“summon” a microglial response, a postulate supported to some
degree by the observation that granulocyte/macrophage colony
stimulating factor (GM-CSF) receptors are up-regulated on
microglial cells adjacent to axotomized facial motor neurons
[63]. Colony stimulating factor-1 (CSF-1) promotes the
proliferation and differentiation of both monocytes [64] and
microglia [65]. In mice lacking this factor (Csf1op/op mutant
mice), only a limited microglial response to peripheral nerve
injury occurs [66]. Microglia do not proliferate or migrate
toward neurons in response to injury, but do undergo minor
morphological changes. Following facial axotomy, a similar
loss of the early stages of microglial activation is observed in
mice in which macrophage colony stimulating factor (M-CSF)
is absent [67]. In this latter model, microglia fail to migrate
across the surface of the axotomized motor neuron and there is a
lack of microglial proliferation. IL-6 knockout mice not only
fail to demonstrate the early microglial response to motor
neuron injury, but also show a reduced astrocytic response, in
keeping with a dual role of IL-6 in both mediating motor
neuron/microglial and microglial/astrocytic interactions [68]. It
is of interest that microglia derived from adult mutant SOD1
transgenic mice show decreased IL-6 production in response to
LPS-stimulated activation compared to controls [37]. This may
be a function of the method of microglial activation.
The chemokine fractalkine has been identified as a
chemoattractant in signaling the microglial response by injured
motor neurons [69–71]. The fractalkine receptor, CX3CR1, is
expressed on both microglia and neurons [72]. Fractalkine
induces proliferation of human microglia in vitro [73]. In
addition to a role in the migration and proliferation of microglia,
fractalkine may also function as a microglial activator as
receptor expression is increased on highly activated, phagocytic
microglia [74]. Through activation of the phosphatidylinositol-
3 kinase/protein kinase B pathway, fractalkine will inhibit Fas
ligand-induced microglial apoptosis through down-regulation
of the pro-apoptotic function of BAD and up-regulation of the
anti-apoptotic activity of BclXL [71] thus promoting microglial
cell survival. A similar effect of fractalkine upon hippocampal
neurons exposed to the HIV envelop protein gp120 has been
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and the nuclear translocation of NF-κB [72,75]. In murine cell
culture experiments fractalkine suppressed the production of
nitric oxide (NO), IL-6 and TNF-α by activated microglia and
suppressed neuronal cell death induced by microglia activated
with LPS and interferon-gamma (IFN-γ), in a dose-dependent
manner. Thus, fractalkine might function as an intrinsic inhi-
bitor against activated microglial-induced neurotoxicity [76]
and may therefore represent a viable target for pharmacological
manipulation in ALS.
Potential candidates for mediating microglia/motor neuron
interactions include a number of pro-inflammatory cytokines
(e.g., IL-1, IL-6 and TNF-α) [77–79] and neurotrophic factors
(e.g., plasminogen, TGF-β, bFGF, BDNF, NGF, NT-3 and NT-
4) [80–82]. IL-1 and TNF-α have similar biological properties
in that at higher concentrations both mimic the cytotoxic effects
of LPS [83]. IL-1 mediates a general inflammatory response that
recruits the further secretion of pro-inflammatory cytokines
(e.g., IL-6, IL-8, colony stimulating factors (CSFs), IFN-α/β)
and can also have a trophic effect. The use of a recombinant IL-
1 receptor antagonist (r-Hu-met Il-1ra) significantly reduces the
volume of damage following brain injury [84]. When IL-1ra-
expressing cells are implanted into the wound of spinal cord
injured rats, a significant suppression of the extent of both
microglial proliferation and NGF up-regulation is observed
[85]. When IL-1 is added to mixed astrocytic/neuronal cultures,
a 5- to 7-fold increase in astrocytes is observed [86].
Ascribing an unambiguous role to TNF-α is more difficult
[87]. When signaling through the TNFR1, TNFR1 recruits a
TNF receptor associated death domain (TRADD) that can then
interact with the Fas-associated death domain to activate caspase
8, leading to downstream activation of effector caspases. TNFR1
and TRADD activation can also lead to NFκB dependent repor-
ter gene expression that in turn drives expression of antiapopto-
tic gene products including survivin, inhibitor of apoptosis
protein-1 (IAP1), IAP2, X-chromosome-linked IAP, Bcl-2,
Bcl-XL, Bfl-1/A1, and FLIP [88]. The interaction of TNF-α or
TNF-β with TNFR2 leads to the activation of NF-κB and the
transcription of a number of possible protective cytokines or
neurotrophic factors. Of interest, knock out mice lacking TNFR2
show a failure to limit the immune response in experimental
autoimmune encephalitis and the use of p74 TNF receptor
(TNFR2) antisense oligonucleotides will increase the extent of a
hypoxic injury [89,90]. Following an ischemic injury, the seve-
rity and extent of brain injury is increased in transgenic mice
lacking the TNF-α receptor [91]. Microglia can also inhibit
sodium nitroprusside (an NO-donor)-induced neuronal apopto-
sis in vitro through a TNF-α dependant mechanism whereas
IL-3, IL-6, bFGF and M-CSF are ineffective in the same experi-
mental paradigm [92]. Hence, the role of TNF-α as a mediator of
microglial/motor neuron interactions is complex, and not a
simple effect of inducing cell death.
5. Deciphering the ambivalence
While the evidence for microglial neurotoxicity in vitro is
extensive, it is important to acknowledge that the function ofglia is to sustain normal neuronal function. In ALS, neuronal
function is compromised. Is it not logical to expect microglia to
react by removing cells damaged beyond the point of repair,
constituting a neuroprotective response? This point is alluded to
by Streit and referred to as “cellular euthanasia” [93]. Although
in vivo evidence for such a phenomenon is lacking, it is an
attractive hypothesis to consider that microglia may accelerate
the death of dying neurons in order to maintain an environment
permissive to the normal function of healthy neurons. However,
this is more likely a process involved in acute rather than
chronic neurodegeneration. Streit proposes that indeed micro-
glial neurotoxicity may contribute to the pathogenesis of
neurodegenerative disease, but this may result more primarily
from microglial senescence rather than aggression [93]. Simi-
larly Wyss-Coray and Mucke postulate that the inflammatory
response is inherently beneficial and that direction and instruc-
tion of inflammatory mediators may be more therapeutic than
suppression of them [94].
An important addition is that the beneficial and harmful
effects of microglia may be a function of their phenotype and
are thus grossly dependent on the nature of the insult. Hence it is
an incorrect assumption to extrapolate the behaviour of LPS-
activated microglia to that of microglia neighbouring degen-
erating motor neurons in vivo. This is supported by the obser-
vation that glutamate uptake by microglia, (a beneficial
behaviour in the context of neurodegenerative disease), and
the cytotoxic potential of microglia varied greatly with the
nature of microglial activation [95]. Similarly, microglia en-
countering regulatory T cells adopt a protective role against β-
amyloid-induced cytotoxicity [96]. Thus microglia are cells
with potentially different or even opposing phenotypes
depending on the environment. Perhaps driving the expression
of a more neurotrophic phenotype would prove effective in
promoting neuronal survival. This concept is reviewed in the
discussion of adaptive immunity in ALS.
6. Adaptive and acquired immunity in ALS?
Microglia and astrocytes are executors of innate immunity
within the CNS. This process begins with the recognition of
abnormality within the neuronal environment by surrounding
glia, which leads to the production of inflammatory mediating
substances and usually phagocytosis of the abnormal cell(s)
recognized via opsonization. However, microglia can proceed to
present antigens to a distinct subset of helper T-cells (Th1 cells)
capable of producing additional cytokines in order to amplify and
generalize the inflammatory response. A study investigating
systemic immune system changes in sporadic ALS revealed that
increased levels of circulating monocytes and macrophages were
observed in all sALS patients and that the degree of activationwas
directly related to the rate of disease progression [97]. Increased
levels ofmonocyte chemoattractant protein-1 (MCP-1) are seen in
the cerebrospinal fluid (CSF) from ALS patients [98,99]. Simi-
larly, increased monocyte and dendritic cell (both antigen
presenting cells) transcripts are seen in tissue from sALS and
fALS patients [25]. These cells present antigen to Th1 cells which
can in turn produce IL-1, IFN-γ, TNF-β, and further activate
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studies using human tissue [19,97,100]. However, the presence of
cells mediating adaptive immunity in the CNS such as Th1
infiltrates is limited to disease end stage time points in mouse
models of ALS [34]. Of interest, driving the adaptive immune
response is protective against mutant SOD1 induced neurode-
generation. Vaccination of SOD1G93A mice with Copaxone
(copolymer-1) led to an increase in lifespan of almost 25%. This
efficacy is thought to result from the sensitization of Th1 cells to
self-antigens. This theoretically leads to an increase in Th1
migration to injured sites, activation, and production of cytokines
and neurotrophins [101]. Protection against β-amyloid and
glutamate excitotoxicity has been achieved through control of
microglial phenotype via the presence or absence ofCD4+CD25+
helper T cells [96]. A series of experiments demonstrated that the
neuroprotection resulting from vaccination with CNS-specific
self-antigens may arise from stimulation of microglia with IFN-γ,
which is produced by reactive helper T cells. This stimulation
results in increased glutamate uptake and decreased NO
production as well as decreased mRNA expression of inflamma-
tory products including COX-2, iNOS, and IκBα (an inhibitor of
NF-κB) by microglia compared to LPS-treated microglia. In
addition, IFN-γ-stimulated microglia had greater antigen-pre-
senting capability and were therefore able to more efficiently
recruit Th1 cells and increase glutamate clearance [95]. The dual
role of microglia as protectors and destructors demands strict
regulation, which is likely performed by the adaptive immune
system and could be intensified by therapies such as vaccination.
Although one downfall to such therapies is the risk of possible
autoimmune disease, in vivo immunization studies using Copa-
xone and myelin-associated antigens have proven successful in
increasing neuronal survival and attenuating behavioural deficits
in both acute and chronic models of neurodegeneration without
evoking autoimmune disease [96,102].
Helper T cells also aid B-cells, effectors of acquired immu-
nity, in immunoglobulin (Ig)G production. While there has been
some controversy regarding the role of IgG in inducing altered
calcium permeability in ALS motor neurons, IgG isolated from
ALS patient serum injected intraperitoneally into mice has been
shown to localize within lower motor neuron axons [103].
Several in vivo studies have demonstrated the ability of pas-
sively transferred ALS IgG to cause recruitment of activated
microglia [104] and motor neuron degeneration in recipient
animals via increased calcium permeability and excitotoxicity
[105,106]. An in vitro experiment demonstrated in mixed pri-
mary spinal cord cultures that IgG from patients with ALS
induces apoptosis via the caspase-3 pathway selectively in
motor neurons [107]. One experiment demonstrated the ability
of ALS IgG to shift the activation curve of calcium current,
indicating an alteration in the voltage dependence of calcium
channels in IgG-treated rat motor neurons [108]. The contro-
versy arises, however, in that others have failed to demonstrate
such effects in rat cerebral synaptosomes, thus concluding that
ALS IgG is ineffective in enhancing presynaptic calcium influx
[109]. Perhaps some specificity exists which makes presynaptic
voltage-sensitive calcium channels on motor neurons exclu-
sively antigenic targets.7. The mediating role of astrocytes
Astrocytes represent a different class of supportive glial cells
that also become reactive in areas of motor neuron degeneration
in ALS. A central role of these cells is to support and sustain
proper neuronal function by regulating extracellular glutamate
levels. Their function as executors of glutamate clearance may
be compromised in ALS. Astrocytes isolated from a mutant
SOD1 transgenic rat show a 3-fold higher expression of
mGluR5 over controls, activation of which fails to lead to
increased glutamate uptake [110]. Although the evidence is
controversial, astrocytes in ALS have been observed to have
decreased expression of the glutamate transporter EAAT2, po-
tentially leading to decreased glutamate transport and sub-
sequent increases in extracellular glutamate [111]. However,
this decrease in expression resulting from alternately spliced
variants of EAAT2 has been demonstrated in normal controls in
addition to ALS patients [112,113].
Monocyte chemoattractant protein-1 (MCP-1) is critical for
migration of monoctyes to areas of injury. As discussed in
relation to adaptive and acquired immunity in ALS, MCP-1
concentrations are significantly increased in both serum and
cerebrospinal fluid (CSF) from ALS patients. MCP-1 immu-
noreactivity is highest in astrocytes in ALS spinal cord,
suggesting that astrocytes have an important role in mediating
the inflammatory response to injury in ALS [98].
Astrocytes can also participate directly in inflammatory
reactions. Like microglia, reactive astrocytes express inflam-
matory markers including iNOS and COX-2 [114] and can
produce proinflammatory mediators including prostaglandins
[115], IL-6 [116] and TNF-α [114]. There is evidence that
reactive astrocytes can even directly induce motor neuron death.
Fibroblast growth factor-1 (FGF-1) released from motor
neurons in response to injury or oxidative stress leads to
accumulation of FGF receptor-1 (FGFR1) in astrocytic nuclei
and stimulates nerve growth factor (NGF) expression and
secretion by astrocytes [117]. This NGF production has been
previously shown to induce motor neuron apoptosis via a p75-
dependent mechanism [118,119]. Fas ligand and TNF-α
produced by reactive astrocytes can also activate death receptors
in injured motor neurons. Returning to the work of Raoul et al.,
ALS motor neurons are particularly susceptible to Fas signaling,
and the apoptotic pathway implicated is motor neuron-specific
[36]. Therefore astrocytes, like microglia, appear to suppress
their trophic activity and adopt a more cytotoxic phenotype with
disease progression. Their loss of glutamate clearing activity
likely contributes significantly to persistent microglial
activation.
8. Anti-inflammatory treatment of ALS
The identification of microglial activation and proliferation
as hallmarks of ALS in vivo and as contributors to motor neuron
death in vitro has led to anti-inflammatory treatment efforts in
mouse models of motor neuron degeneration.
Support for the role of microglia in motor neuron degene-
ration is also gained from the observation that the administration
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free interval prior to the onset of motor dysfunction by roughly
9–20% in various mutant SOD1 transgenic mice and extends
survival by 13–25% (in multidrug cocktails in which minocy-
cline is included ) [120–122]. It has also been shown to reduce
the extent of motor neuron microvacuolar degeneration at 120
days [123].Minocycline is a second-generation tetracycline with
distinct antibiotic and anti-inflammatory properties [124–126].
The site of action of minocycline appears to be at both the level
of the microglia in which the up-regulation of iNOS is inhibited,
and at the target cell where the release of mitochondrial cyto-
chrome c (and thus the initiation of a pro-apoptotic pathway) is
inhibited [127–130]. The neuroprotective effects of minocycline
are thought to result from inhibition of microglial activation
[131,132] and possibly proliferation [133]. These results led to
phase I/II studies of minocycline in ALS patients [134]. Al-
though no difference was observed between treated and un-
treated groups in these studies, pivotal phase III trials are
ongoing. It is noteworthy that in addition to its anti-inflam-
matory effects, minocycline has been shown to also have anti-
apoptotic [135,136], antioxidant [137,138], and anti-glutama-
tergic effects [136,138]. Therefore caution must be taken when
attributing its efficacy in mouse models to treatment of inflam-
mation alone.
Celecoxib (Celebrex) and rofecoxib are inhibitors of COX-2.
Treatment with these COX-2 inhibitors combined with creatine
increased survival by up to 30% in SOD1 mutant mice [139–
141] while treatment with a non-specific COX inhibitor (sulin-
dac) extended survival by roughly 10% [142]. It should be
noted, however, that to date none of the COX inhibitors tested
have shown efficacy in human ALS patients. Celecoxib, deve-
loped for the treatment of rheumatoid arthritis, continues to be
tested in a variety of neurodegenerative diseases considered to
have inflammatory components.
It is likely that treatment targeting microglial activation and
the production of inflammatory mediators will have to be
combined with cellular or molecular therapies treating neuronal
abnormalities that lead to the initial recruitment of microglia.
9. Conclusion
Although evidence appears to suggest a role for microglia and
their inflammatory products in the pathogenesis of ALS, the
most significant pieces of information remain elusive. Most
importantly, what causes the initial priming of microglia? Do
microglia respond to primary stimuli from predisposed motor
neurons and take on a protective role, or is ALS a disease with
auto-immune characteristics? Wyss-Coray and Mucke suggest
that abnormal protein accumulation or other signals emanated
from affected motor neurons may summon microglia and trigger
their activation [94]. This is supported by evidence that mutant
SOD1 secreted from neurons can activate microglia and lead to
neuronal death [143]. Other studies suggest, however, that in
ALS, microglia can have cytotoxic potential regardless of the
health status of neighbouring motor neurons [11]. Does then the
role of microglia in pathogenesis depend on whether they too are
predisposed as indicated by these chimeric studies? The resultsof minocycline treatment of mutant SOD1 mice suggest that
microglial activation is concomitant with and contributes to
disease progression. However, no benefit of the inhibition of
microglial activation has been observed in human patients. As
discussed previously, ALS is clearly a multi-factorial disease in
which complex neuronal–glial interactions exist. Hence, it is
important that molecular communication between neurons and
glia be studied comprehensively in both healthy and diseased
states. It is also important that the relationships between various
pathological features of ALS intrinsic to motor neurons them-
selves and the glial inflammatory response are studied indepen-
dently to determine which abnormalities could be triggering
inflammation. Although mutant SOD1 models allow for vali-
dation of potential treatments, they do not necessarily facilitate
understanding of particular underlying pathophysiological me-
chanisms contributing to disease initiation.
The cells of the immune system, including the tissue-specific
macrophages like microglia, are capable of coordinating highly
selective attacks on specific target cells based on principles of
recognition. Immunity is therefore a process that is potentially
altered in ALS and, as such, is an intriguing candidate for
therapeutic intervention. This is not to say that ALS is a disease
of cells of the macrophage lineage. Rather, the evidence sug-
gests that ALS is a disease in which inflammation remains a
theoretically beneficial process. It is the ambivalent nature of
activated microglia that not only creates controversy as to their
role in the pathogenesis of ALS, but also offers therapeutic
potential as a useful tool in the modulation of factors influen-
cing motor neuron death in ALS such as release of inflam-
matory mediators with pro-apoptotic effects and extracellular
glutamate clearance. Perhaps, inflammation is a key determi-
nant of the ALS disease process, but its elimination as a thera-
peutic objective may be less successful than its modulation.
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